Perrigo gets FDA final approval for generic version of Exalgo® 32mg extended release tablets
DUBLIN: Perrigo Company plc announced it has received final approval from the U.S. Food and Drug Administration (FDA) for its AB-rated Abbreviated New Drug Application referencing Exalgo® 32mg extended-release tablets (hydromorphone HCl). The company anticipates launching this product by the end of September 2017.
Exalgo® 32mg extended-release tablets (hydromorphone HCl) is an opioid agonist indicated for the management of moderate to severe pain in opioid-tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Annual market sales for the brand and generic equivalents of Exalgo® 32mg extended release tablets for the 12 months ended July 2017were approximately $35 million.
Perrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, "This final approval exemplifies Perrigo's commitment to developing quality, high-value alternatives in important treatment categories. The Rx team continues to leverage our development capabilities to deliver Quality Affordable Healthcare Products® to customers, consumers and families around the world."
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd